Human ALDOC ELISA Kit (V2LY-0626-LY4206)

Izraely, S., Ben‐Menachem, S., Sagi‐Assif, O., Meshel, T., Malka, S., Telerman, A., ... & Witz, I. P. (2021). The melanoma brain metastatic microenvironment: aldolase C partakes in shaping the malignant phenotype of melanoma cells–a case of inter‐tumor heterogeneity. Molecular Oncology, 15(5), 1376-1390.

Yuan, J., Xing, H., Li, Y., Song, Y., Zhang, N., Xie, M., ... & Yang, M. (2021). EPB41 suppresses the Wnt/β-catenin signaling in non-small cell lung cancer by sponging ALDOC. Cancer Letters, 499, 255-264.

Chang, Y. C., Tsai, H. F., Huang, S. P., Chen, C. L., Hsiao, M., & Tsai, W. C. (2019). Enrichment of aldolase C correlates with low non-mutated IDH1 expression and predicts a favorable prognosis in glioblastomas. Cancers, 11(9), 1238.

Pamidimukkala, N. V., Leonard, M. K., Snyder, D., Mccorkle, J. R., & Kaetzel, D. M. (2018). Metastasis suppressor NME1 directly activates transcription of the ALDOC gene in melanoma cells. Anticancer research, 38(11), 6059-6068.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols